JP2005533791A5 - - Google Patents

Download PDF

Info

Publication number
JP2005533791A5
JP2005533791A5 JP2004513273A JP2004513273A JP2005533791A5 JP 2005533791 A5 JP2005533791 A5 JP 2005533791A5 JP 2004513273 A JP2004513273 A JP 2004513273A JP 2004513273 A JP2004513273 A JP 2004513273A JP 2005533791 A5 JP2005533791 A5 JP 2005533791A5
Authority
JP
Japan
Prior art keywords
morpholine
benzyl
phenoxy
ethoxy
salt according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004513273A
Other languages
English (en)
Japanese (ja)
Other versions
JP4563172B2 (ja
JP2005533791A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/005261 external-priority patent/WO2003106441A1/en
Publication of JP2005533791A publication Critical patent/JP2005533791A/ja
Publication of JP2005533791A5 publication Critical patent/JP2005533791A5/ja
Application granted granted Critical
Publication of JP4563172B2 publication Critical patent/JP4563172B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004513273A 2002-06-17 2003-06-04 レボキセチンの医薬用塩 Expired - Fee Related JP4563172B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02077366 2002-06-17
PCT/EP2003/005261 WO2003106441A1 (en) 2002-06-17 2003-06-04 Pharmaceutical salts of reboxetine

Publications (3)

Publication Number Publication Date
JP2005533791A JP2005533791A (ja) 2005-11-10
JP2005533791A5 true JP2005533791A5 (https=) 2006-07-20
JP4563172B2 JP4563172B2 (ja) 2010-10-13

Family

ID=29724495

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004513273A Expired - Fee Related JP4563172B2 (ja) 2002-06-17 2003-06-04 レボキセチンの医薬用塩

Country Status (23)

Country Link
US (2) US20070010517A1 (https=)
EP (1) EP1515959B1 (https=)
JP (1) JP4563172B2 (https=)
KR (1) KR100779786B1 (https=)
CN (2) CN1662511B (https=)
AR (1) AR040222A1 (https=)
AT (1) ATE439354T1 (https=)
AU (1) AU2003227755B2 (https=)
BR (1) BR0311878A (https=)
CA (1) CA2489763C (https=)
DE (1) DE60328787D1 (https=)
DK (1) DK1515959T3 (https=)
ES (1) ES2328472T3 (https=)
MX (1) MXPA04011916A (https=)
MY (1) MY131231A (https=)
NO (1) NO329346B1 (https=)
NZ (1) NZ537023A (https=)
PE (1) PE20040565A1 (https=)
PL (1) PL375211A1 (https=)
RU (1) RU2286341C2 (https=)
TW (1) TWI267510B (https=)
WO (1) WO2003106441A1 (https=)
ZA (1) ZA200409624B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0319793D0 (en) 2003-08-22 2003-09-24 Lilly Co Eli Pyridinylmorpholine derivatives
WO2005082869A1 (en) * 2004-02-20 2005-09-09 Pharmacia & Upjohn Company Llc Method for the preparation of aryl ethers
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20190185438A1 (en) * 2016-12-06 2019-06-20 Tonix Pharmaceuticals Holding Corp. Salts and polymorphs of esreboxetine
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2167407B (en) * 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
AU9214498A (en) * 1997-09-23 1999-04-12 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
IT1305322B1 (it) * 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
US6465458B1 (en) * 1999-07-01 2002-10-15 Pharmacia & Upjohn Company Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor

Similar Documents

Publication Publication Date Title
JP2019059760A5 (https=)
JP2011527333A5 (https=)
RU2005128548A (ru) Применение (1s,2r) этантиомера милнаципрана для получения лекарственного средства
JP2002501025A5 (https=)
JP2011524850A5 (https=)
JP2023143940A5 (https=)
JP2006514095A5 (https=)
JPS62190160A (ja) (−)−ベンツヒドリルスルフイニルアセトアミド及びその製法
JP5423905B2 (ja) 新規化合物及びその医薬用途
JP2008521827A5 (https=)
JP2007533722A5 (https=)
CN115315426A (zh) Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法
JP2009062388A5 (https=)
JP2004532828A5 (https=)
RU2011123890A (ru) Кристаллическая форма 4-[2-(2-фторфеноксиметил)фенил]пиперидинового соединения
JP2005508872A5 (https=)
JP2005533791A5 (https=)
JP2009040767A5 (https=)
MX2023012521A (es) Formas en estado solido de (s)-n-(3-(2-((r)-1-hidroxipropano-2-il) amino)-6-morfolinopiridin-4-il)-4-metilfenil)-3-(2,2,2-trifluoroe til)pirrolidin-1-carboxamida y sales de las mismas.
RU2005100846A (ru) Фармацевтические соли ребоксетина
RU2013105479A (ru) Кристаллическая форма соединения 3-феноксиметилпирролидина
ATE295845T1 (de) Prucaloprid-n-oxid
JP5435165B2 (ja) 医薬用途
SE0203778D0 (sv) A new oral immediated release dosage form
JP2007523176A5 (https=)